Nano Vibronix, Inc. NAOV
We take great care to ensure that the data presented and summarized in this overview for NanoVibronix, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NAOV
View allLatest Institutional Activity in NAOV
Top Purchases
Top Sells
About NAOV
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Insider Transactions at NAOV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 05
2023
|
Thomas Mika Director |
BUY
Open market or private purchase
|
Direct |
50,000
+50.0%
|
$0
$0.25 P/Share
|
|
Jun 15
2022
|
Christopher M Fashek Director |
BUY
Open market or private purchase
|
Direct |
40,000
+34.78%
|
$0
$0.6 P/Share
|
|
Jun 14
2022
|
Stephen Russell Brown Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$0
$0.57 P/Share
|
|
Jun 01
2022
|
Aurora Cassirer Director |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$0
$0.69 P/Share
|
|
Sep 29
2020
|
Christopher M Fashek Director |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$0
$0.79 P/Share
|
|
Nov 20
2019
|
Christopher M Fashek Director |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$50,000
$2.0 P/Share
|